Why LENZ Therapeutics (LENZ) Is Up 32.2% After FDA Approves First Aceclidine Eye Drop for Presbyopia

• On July 31, 2025, LENZ Therapeutics announced that the US FDA approved VIZZ (aceclidine ophthalmic solution) 1.44% as the first and only aceclidine-based eye drop for the treatment of presbyopia in adults, following positive Phase 3 clinical trial results.
• This approval introduces a new chemical entity in the US ophthalmic space, enabling LENZ to initiate immediate sales and marketing with anticipated product availability by mid-fourth quarter 2025.
• We'll explore how the first-in-class approval of VIZZ amplifies LENZ Therapeutics' investment narrative and future market opportunities.

Find companies with promising cash flow potential yet trading below their fair value.

What Is LENZ Therapeutics' Investment Narrative?

For shareholders of LENZ Therapeutics, the investment thesis hinges on belief in the company’s ability to convert scientific innovation into commercial success, particularly after the FDA’s approval of VIZZ as the first aceclidine-based treatment for presbyopia. This milestone is clearly material, transforming LENZ’s short-term outlook by unlocking immediate revenue potential and elevating expectations for product adoption as the company launches direct sales and marketing. However, with only $5 million in revenue last quarter against continued net losses and a Price-To-Book far above industry averages, sustainable profitability remains a key hurdle. The regulatory win refocuses near-term catalysts on VIZZ’s upcoming launch and initial sales traction, while shifting risk toward execution: whether LENZ can scale distribution, manage possible side effects, and deliver on anticipated high growth. The recent surge in share price reflects changing expectations but increases sensitivity to setbacks. In contrast, execution risk in launching VIZZ is now front and center for investors.

LENZ Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

The Simply Wall St Community’s three fair value views range from US$45 to a very large US$1,361.31 per share. While these opinions stretch widely, the FDA approval adds a fresh catalyst and could influence future expectations about LENZ’s profitability and market position. Explore how differing forecasts can shape sentiment and inform your outlook.

Explore 3 other fair value estimates on LENZ Therapeutics - why the stock might be worth just $45.00!

Build Your Own LENZ Therapeutics Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your LENZ Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free LENZ Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LENZ Therapeutics' overall financial health at a glance.

Ready For A Different Approach?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 26 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com